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ABSTRACT
Background: Birt–Hogg–Dube ´ syndrome (BHDS) (MIM
135150) is an autosomal dominant predisposition to the
development of follicular hamartomas (fibrofolliculomas),
lung cysts, spontaneous pneumothorax, and kidney
neoplasms. Germline mutations in BHD are associated
with the susceptibility for BHDS. We previously described
51 BHDS families with BHD germline mutations.
Objective: To characterise the BHD mutation spectrum,
novel mutations and new clinical features of one
previously reported and 50 new families with BHDS.
Methods: Direct bidirectional DNA sequencing was used
to screen for mutations in the BHD gene, and insertion
and deletion mutations were confirmed by subcloning. We
analysed evolutionary conservation of folliculin by
comparing human against the orthologous sequences.
Results: The BHD mutation detection rate was 88% (51/
58). Of the 23 different germline mutations identified, 13
were novel consisting of: four splice site, three deletions,
two insertions, two nonsense, one deletion/insertion, and
one missense mutation. We report the first germline
missense mutation in BHD c.1978A.G (K508R) in a
patient who presented with bilateral multifocal renal
oncocytomas. This mutation occurs in a highly conserved
amino acid in folliculin. 10% (5/51) of the families had
individuals without histologically confirmed fibrofolliculo-
mas. Of 44 families ascertained on the basis of skin
lesions, 18 (41%) had kidney tumours. Patients with a
germline BHD mutation and family history of kidney
cancer had a statistically significantly increased probability
of developing renal tumours compared to patients without
a positive family history (p=0.0032). Similarly, patients
with a BHD germline mutation and family history of
spontaneous pneumothorax had a significantly increased
greater probability of having spontaneous pneumothorax
than BHDS patients without a family history of
spontaneous pneumothorax (p=0.011). A comprehen-
sive review of published reports of cases with BHD
germline mutation is discussed.
Conclusion: BHDS is characterised by a spectrum of
mutations, and clinical heterogeneity both among and
within families.
Birt–Hogg–Dube ´ syndrome (BHDS) (MIM 135150)
is an autosomal dominantly inherited genoderma-
tosis that predisposes to the development of
cutaneous hamartomas (fibrofolliculomas), kidney
neoplasms, lung cysts and spontaneous pneu-
mothorax.
12 We mapped the BHD locus to
the short arm of chromosome 17(17p11.2).
3
Subsequently, we found that germline mutations
in BHD (GenBank accession number AF517523)
(also known as FLCN), were associated with the
susceptibility for BHDS.
4 BHD is composed of 14
exons. We previously reported 51 BHDS families
with germline mutations in BHD, and to date
more than 40 unique mutations in BHD have been
reported.
4–16 Germline insertion or deletion of a
cytosine in the hypermutable polycytosine (C8)
tract in exon 11 of the BHD gene has been
detected in 53% of BHDS families and is suggested
as a mutation ‘‘hot spot’’.
6 Most BHD germline
mutations are frameshift or nonsense mutations
that are predicted to truncate the BHD protein,
folliculin.
4–16
Two naturally occurring renal cancer syndromes
in animals have been described: hereditary multi-
focal renal cystadenocarcinoma and nodular der-
matofibrosis in German shepherd dogs
17 18 and
hereditary renal carcinoma in the Nihon rat.
19 20
Germline mutations in the BHD ortholog genes
have been identified in affected animals with these
renal cancer syndromes: a missense mutation in
exon 7 in the canine bhd gene,
21 and an insertion of
a cytosine in a C5 tract in the rat bhd gene.
22
Furthermore, a high frequency of loss of hetero-
zygosity (LOH) of the wild type bhd allele has been
demonstrated in renal tumours in Nihon rats
suggesting that BHD functions as a tumour
suppressor gene.
19 20
BHD is predicted to encode a 579 amino acid
protein, folliculin, which is highly conserved
among species. BHD mRNA is expressed in a
variety of tissues including stromal cells, the distal
nephron of the kidney, type I pneumocytes of the
lung, and skin and its appendages.
23 However,
reduced expression of BHD was seen in renal
tumours from patients with BHDS,
23 consistent
with the reported inactivation of the wild-type
BHD allele by somatic mutation or LOH in BHD
associated renal tumours.
24
Until recently the function of folliculin was
unknown. Taking a genetic approach, Singh and
colleagues demonstrated that Drosophila DBHD is
required for male germline stem cell maintenance
in the fly testis and functions downstream of the
JAK/STAT and decapentaplegic signal transduc-
tion pathways.
25 Recently, Baba and colleagues
identified a novel folliculin-interacting protein,
FNIP1, by co-immunoprecipitation studies in
mammalian cells. They found that FNIP1 binds
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mTOR suggesting that folliculin and its interacting partner may
be involved in the AMPK and mTOR signalling pathways.
26
Understanding the mutation spectrum as well as defining the
clinical features of BHDS is important for diagnosis and BHD
mutation screening, as well as for surveillance and treatment. In
this study, we investigated new clinical features, BHD germline
mutations, and potential genotype–phenotype associations in
51 families with BHDS.
PATIENTS AND METHODS
Patient recruitment and evaluation
All patients were evaluated at the National Institutes of Health
(NIH) Clinical Center in consecutive order in a protocol
approved by the Institutional Review Board of the National
Cancer Institute (NCI). All members of families screened for
BHDS who participated in this study gave written informed
consent. We recruited BHDS families through referrals from the
11 000 members of the American Academy of Dermatology and
were also referred families for treatment of familial kidney
cancer. Forty-four families were ascertained because of cuta-
neous signs of BHDS and seven families were referred to the
Urologic Oncology Branch for evaluation and treatment of
familial kidney cancer. Medical histories were obtained (fibro-
folliculomas, spontaneous pneumothorax and renal tumours)
and physical examinations were performed. History of other
neoplasms and pneumothorax in the patient or family were also
recorded. Each individual had a detailed dermatologic examina-
tion and skin biopsies were obtained of selected lesions.
Computed tomography (CT) scans of the chest and abdomen
were used to screen for pulmonary and renal abnormalities
respectively, as previously described.
6 Outside medical records
and pathology reports were reviewed, and tissue specimen
blocks and slides were reviewed by NIH pathologists. Blood was
drawn for BHD mutation analysis.
BHD mutation analysis
DNA was extracted from peripheral blood leucocytes according
to standard procedures. Methods for identification of exon/
intron boundaries and high throughput DNA sequencing were
as previously described.
4 At least 160 unrelated control
individuals were examined for each disease associated sequence
variant. Insertion and deletion mutations were confirmed by
subcloning using Topo Cloning Kit (Invitrogen) and sequencing.
Statistical analysis
Data collected from BHDS patients included: presence of
fibrofolliculomas, presence of renal tumours, gender, history
and number of pneumothoraces, and presence of lung cysts.
Analyses with respect to dichotomous parameters and their
relationship to presence or absence of a pneumothorax, renal
tumour or fibrofolliculomas were done using a Fisher’s exact
test. Mehta’s modification to Fisher’s exact test was used to
compare unordered categorical data to a dichotomous para-
meter.
27 An exact Cochran–Armitage test for trend was used to
determine the association between the number of pneu-
mothoraces considered in ordered categories, and the presence
or absence of a family history of pneumothoraces.
28 All p values
are two-sided and were not adjusted for multiple comparisons.
However, in view of the exploratory nature of the study and the
large number of comparisons performed, only p values ,0.01
should be considered as being associated with statistically
significant tests, while those between 0.01 and 0.05 would be
considered trends.
Multiple sequence alignment of the folliculin protein
We analysed evolutionary conservation by comparing human
folliculin against the orthologous folliculin sequences of
chimpanzee, monkey, mouse, rat, dog, horse, cow, chicken,
frog, zebrafish and sea urchin from the National Center for
Biotechnology information (NCBI) protein database.
29 The
ClustalW Multiple Sequence Alignments algorithm (European
Bioinformatics Institute) was used to evaluate sequence
conservation.
30
Literature review
We performed an electronic search from 2001 to 2007 designed
to capture all reported cases of BHDS with BHD (also known as
FLCN) germline mutations. Cases were excluded if mutations
were somatic (not shown in a second tissue like normal kidney
or peripheral blood). However, cases were still included in the
review even if the method of mutation detection was not
included. In total, 11 articles were ultimately included.
5–15 Cases
were cross-referenced in order to avoid duplication of cases.
Only one case was reported twice.
78Germline BHD mutation,
presence of fibrofolliculomas, renal tumours, lung cysts, and
history of pneumothorax, regardless of radiological methods,
were recorded.
RESULTS
BHD mutation analysis
Ninety-eight individuals from 58 families were screened for
BHD mutations. Using direct sequencing analysis we identified
BHD germline mutations in 89 individuals from 51 families with
BHDS (88% (51/58) BHD mutation detection rate). Direct
sequence analysis of the 14 coding exons and splice site
junctions of BHD revealed 23 unique germline mutations
including: one missense, eight deletions, four insertions, one
insertion/deletion, three nonsense, and six splice site mutations
(table 1). Of these 23 germline mutations, 13 were novel and
consisted of: three deletions (c.602delA, c.1707delC, c.1983-
5delGAG), two insertions (c.802insA, c.1741insA), an insertion/
deletion (c.774-5delGTinsCAC), four splice site mutations
(IVS4-2 A.G, IVS7+1G .T, c.1755 G.A, IVS12+1G .A), one
missense (c.1978A.G [K508R]) and two nonsense (c.1065-
6delGCinsTA, c.1670C.G) (table 1, fig 1). Splice site and
missense mutations were not detected in more than 160 normal
individuals. All insertions and deletions were confirmed by
subcloning. The c.1755 G.C and c.1755 G.A affect the last
coding nucleotide of exon 11 resulting in aberrant mRNA
splicing. Splicing alteration of exon 11 as a consequence of this
mutation has been previously demonstrated.
7
BHD mutations were identified affecting only translated
exons 4, 5, 6, 9, 11, 12 and 13 (table 1). Exon 11 was the most
frequent site of mutation representing 47% (24/51) of the BHDS
families. A total of 19 families had a germline BHD mutation in
the mononucleotide tract of eight cytosines (c.1733–1740), the
mutation ‘‘hotspot’’ in exon 11. Seventy-four per cent (14/19)
had a cytosine insertion (c.1733insC) and 26% (5/19) had a
cytosine deletion (c.1733delC). Three of the four families with
mutations in exon 12 shared a common mutation (c.1844C.G).
Four families had a BHD mutation in exon 5. Exons 9 and 6
were each the site of mutations in three families. All three
families with mutations in exon 9 had the 28-bp duplication
(c.1378-1405dup). Two families had unique mutations in exon 4
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Family
ID
Mutation analysis Phenotype in family members
Intron Exon Nucleotide change
Codon
location Mutation type
No. clinical
affected
No. with
FF
Other skin
lesions
No. with
renal tumours
No. with
lung cysts
No. with
pneumo-thorax
251 4 c.514delT{ F20 Deletion 1 1 TD, BCC 0 0 0
252 4 c.602delA E49 Deletion 1 1 0 1 1 (n=3)
253 4 IVS4-2A.G Splice site 1 1 0 1 1 (n=1)
240 4 IVS4-2A.G Splice site 10 9 TD, PFF 1 4 0
254 4 IVS4-2A.G Splice site 1 1 TD 1 1 0
255 4 IVS4-2A.G Splice site 1 1 PFF 0 1 1 (n=2)
256* 5 c.751delA D99 Deletion 1 0 PFF 1 1 1 (n=5)
1798 5 c.774-5delGTinsCAC V107 Deletion/ insertion 1 1 TD 0 1 0
257 5 c.774-5delGTinsCAC V107 Deletion/ insertion 4 3 PFF, SH 0 4 0
258 5 c.802insA Q116 Insertion 1 1 LM 1 1 1 (n=17)
259 6 c.1039delG{ G195 Deletion 1 1 1 1 0
260 6 c.1039delG{ G195 Deletion 1 1 SH, PFF 0 1 1 (n=1)
1751 6 c.1065-6delGCinsTA A204X Nonsense 4 4 AF, BCC 0 4 2 (n=2)
261 7 IVS7+1G .T Splice site 1 1 L 1 1 1 (n=3)
262 7 IVS7+1G .T Splice site 5 4 AF, DFSP, LS,
TD
45 1 ( n = 1 )
263* 7 IVS7+1G .T Splice site 1 1 1 1 1 (n=1)
264 9 c.1378-1405dup T317 Insertion 1 1 PFF 1 1 0
265 9 c.1378-1405dup T317 Insertion 2 2 PFF 1 2 2 (n=4)
266 9 c.1378-1405dup T317 Insertion 1 1 TD 0 1 0
267 9 IVS9+2T .G Splice site 1 1 0 1 0
268 11 c.1670C.G Y405X Nonsense 1 1 DF 1 1 0
269 11 c.1707delC L418 Deletion 1 0 AF, SH, SCC 0 1 0
270 11 c.1733insC H429 Insertion 1 1 MM, L 1 0 0
271 11 c.1733insC H429 Insertion 2 2 TD, PFF, CTN 0 1 0
272 11 c.1733insC H429 Insertion 1 1 BCC, PFF 0 1 0
273 11 c.1733insC H429 Insertion 1 1 PFF 0 1 0
274 11 c.1733insC H429 Insertion 1 1 PFF, SH 0 1 1 (n=4)
275 11 c.1733insC H429 Insertion 2 2 1 2 1 (n=5)
276 11 c.1733insC H429 Insertion 1 1 BCC 0 0 0
277 11 c.1733insC H429 Insertion 2 2 PFF 0 2 0
278 11 c.1733insC H429 Insertion 3 2 PFF 0 2 0
279* 11 c.1733insC H429 Insertion 2 2 2 2 1 (n=1)
280 11 c.1733insC H429 Insertion 3 2 AF, CTN 0 3 3 (n=5)
281 11 c.1733insC H429 Insertion 2 2 AF 0 2 1 (n=5)
282 11 c.1733insC H429 Insertion 1 1 1 1 0
283 11 c.1733insC H429 Insertion 3 2 1 3 1 (n=1)
284 11 c.1733delC H429 Deletion 4 3 L, MM 1 4 3 (n=4)
285* 11 c.1733delC H429 Deletion 1 1 1 1 1 (n=7)
286 11 c.1733delC H429 Deletion 1 1 0 1 0
287 11 c.1733delC H429 Deletion 1 0 TD 1 1 1 (n=1)
288 11 c.1733delC H429 Deletion 2 2 AF 2 2 0
289 11 c.1741insA H429 Insertion 1 1 BCC, SCC 0 1 1 (n=3)
290* 11 c.1755G.C E434Q Splice site 1 1 1 0 0
291* 11 c.1755G.A E434K Splice site 2 1 PFF 1 2 1 (n=4)
292 12 c.1834-5delTC L460 Deletion 1 1 1 1 1 (n=1)
293 12 c.1844C.G Y463X Nonsense 2 2 AF 0 2 1 (n=2)
294 12 c.1844C.G Y463X Nonsense 1 0 PFF, AF 0 0 0
295 12 c.1844C.G Y463X Nonsense 1 1 AF 1 1 1 (n=4)
296 12 IVS12+1G.A Splice site 1 1 TD, PFF 0 1 1
297* 13 c.1978A.G K508R Missense 1 0 0 1 0 0
298 13 c.1983-5delGAG E510 Deletion 2 1 AF 0 2 2 (n=4)
Totals: 51 families 89 75 30 75
AF, angiofibroma; BCC, basal cell carcinoma; CTN, connective tissue nevus; DFSP, dermatofibrosarcoma protuberans; FF, fibrofolliculoma; L, lipoma; LM, cutaneous leiomyoma;
MM, malignant melanoma; PFF, perifollicular fibroma; LS, cutaneous leiomyosarcoma; SCC, squamous cell carcinoma; SH, sebaceous hyperplasia; TD, trichodiscoma.
FF diagnosis is based on histological diagnosis only.
*Families ascertained on the basis of kidney tumours. {In these cases of deletions in a mononuclear tract, the last nucleotide is given. The c.514delT mutation was formerly reported
as c.513delT and the c.1039delG was formerly reported as c. 1036delG.
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J Med Genet 2008;45:321–331. doi:10.1136/jmg.2007.054304 323Figure 1 BHD mutations newly characterised in families with Birt–Hogg–Dube ´ syndrome (BHDS). Sequencing chromatograms of genomic DNA from
control subjects and patients are shown on the left. The arrows indicate the position of the identified nucleotide changes. The corresponding pedigrees
are shown on the right. FF, fibrofolliculoma; MT, mutant; WT, wildtype.
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families had intronic mutations that were predicted to cause
exon skipping: three in intron 7 (IVS7+1G.T), four in intron 4
(IVS4-2 A.G), one in intron 9 (IVS9+2T .G) and one in intron
12 (IVS12+1G .A) (table 1). The most 59 mutation (c.514delT)
occurred in exon 4 (20 aa from the initiation codon) and is
predicted to truncate the protein 34 amino acids downstream.
The most 39 mutation (c.1983-5delGAG) occurred in exon 13
and it is predicted to produce a deletion of a single amino acid at
position 510.
The novel missense mutation (K508R) was also confirmed by
a CLIA approved laboratory and it was not present in DNA
from 160 unrelated control individuals. The K508R mutation
leads to a change from lysine to arginine at amino acid position
508 (fig 2). ClustalW multiple protein sequence alignments
showed that amino acid K508 of folliculin is highly conserved in
chimpanzee, horse, mouse, rat, dog, cow, chicken, zebrafish and
sea urchin (fig 2). In addition, a block of continuous high
conservation was shown between amino acids L507 to V515.
The conservation across species suggests an important biological
role for K508 amino acid in folliculin.
Clinical features
Patients’ clinical characteristics are listed in table 1. Our cohort
included a total of 89 individuals from 51 families with BHD
mutations. There were 37 men and 52 women with a median
age of 54 years. The number of affected individuals in a family
ranged from 1 to 10. Thirty-three families had only one member
affected with BHDS who participated in the study.
Cutaneous findings
Ninety per cent (46/51) of families with BHDS had individuals
with multiple 1–5 mm white or skin coloured papules
distributed over the face, neck and/or upper trunk and a
histologically confirmed fibrofolliculoma (FF). Fifty-seven per
cent (26/46) of BHDS families with a histologically confirmed
FF also had individuals with a second histologically confirmed
cutaneous lesion associated with BHDS including: angiofibroma
(AF) or trichodiscoma (TD) (12 families), perifollicular fibroma
(PFF) (11 families), and both TD and PFF (three families). In
10% (5/51) of BHDS families the clinical diagnosis of FF was not
confirmed histologically. However, four of these families had at
least one individual with a histologically proven TD or AF (one
individual in each of two families), or PFF (one individual in one
family), or both an AF and a PFF (one individual in one family).
One family had no individuals with FF, PFF, TD or AF. All of
these individuals also had a germline BHD mutation. In
addition, three of these families had individuals with a history
of spontaneous pneumothorax and/or lung cysts supporting the
clinical diagnosis of BHDS.
Other dermatologic conditions histologically confirmed in
individuals with a germline BHD mutation included: basal cell
carcinoma (four families), connective tissue nevus (two
families), sebaceous hyperplasia (two families), squamous cell
Figure 2 Novel BHD missense mutation (K508R). (A) Genomic sequence of control. (B) Genomic sequence of BHDS patient with the c.1978A.G
(K508R) mutation. (C) Multiple sequence alignment. The amino acid residues are coloured according to their chemical properties. (D) Degree of
conservation. The numerical index reflects the degree of conservation of the physical–chemical properties in the alignment. Star (*) indicates amino
acids 100% identical in the alignment (highest score). The next most conserved group is composed of substitutions in amino acids with the same
physical chemical class.
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families) (table 1). Two families had cutaneous soft tissue
tumours: family 258 had one individual with a cutaneous
leiomyoma (LM) and family 262 had one individual with a
dermatofibrosarcoma protuberans (DFSP) and another with a
cutaneous leiomyosarcoma (LS).
Kidney tumour findings
Overall 34% (30/89) of individuals and 49% (25/51) of families
with BHDS had kidney tumours (table 1). Men (13 cases)
developed renal tumours about as often as women (17 cases).
Patients had either bilateral, multifocal or unilateral renal
tumours (.0.5 cm lesion).
Among 25 families with kidney tumours, 18 (72%) were
recruited based on cutaneous manifestations suggestive of
BHDS and/or the histologic diagnosis of fibrofolliculoma and
seven (28%) were recruited based on kidney tumours.
Approximately 41% (18/44) of families presenting with
cutaneous manifestations had kidney tumours. We observed
that 88% of BHDS families with renal tumours had only one
individual with renal tumours even after screening multiple
BHD gene mutation carriers for renal tumours with abdominal
CT or magnetic resonance imaging (MRI) of the kidneys. Only
three families had multiple living individuals affected with
kidney tumours. Family 279 and family 288 each had two living
cases and family 262 had four cases. An individual from family
297 with a germline BHD mutation presented with bilateral
multifocal renal oncocytomas as the only sign of BHDS. He had
no skin papules, history of pneumothorax or lung cysts on CT
imaging.
Pulmonary findings
Eighty-eight per cent (45/51) of the BHDS families and 84% (75/
89) of BHDS patients had lung cysts on CT imaging (table 1).
Fifty-three per cent (27/51) of BHDS families and 38% (34/89)
of individuals with BHDS had a history of spontaneous
pneumothorax. Most patients with a history of pneumothorax
had lung cysts by chest CT imaging (table 1). Thirty-four
individuals had a total of 92 spontaneous pneumothoraces.
Nineteen patients had two pneumothoraces, three patients had
four pneumothoraces, three had five pneumothoraces, and one
experienced seven pneumothoraces (table 1).
Family history
We found that 18 of 31 patients (58%) with a family history of
pneumothorax developed pneumothoraces compared to 16 of 57
patients (28%) without this family history (p=0.011). Among
patients with BHDS, there was a statistically significant trend
toward having a greater number of pneumothoraces if the
patients had a family history of pneumothoraces compared to
the number of pneumothoraces in patients who did not have
this family history (p=0.0022, by an exact Cochran–Armitage
trend test). However, family history of pneumothorax was not
associated with an increased risk of kidney tumours. Twelve of
34 patients with a family history of pneumothoraces had kidney
tumours compared to 18 of 55 without this family history
(p=0.82).
BHDS patients with a family history of kidney tumours had a
statistically significantly increased probability of having renal
tumours, with 16 of 28 (57%) individuals having these tumours
among those with a family history for this condition as
compared to 14 of 61 (23%) without a family history of kidney
tumours (p=0.0032). However, we observed that a family
history of renal tumours was not associated with an increased
risk of lung cyst (p=0.32) or pneumothrorax (p=0.16).
Variable expression of phenotypic manifestations
Variable phenotypic expression may be observed among families
and within members of BHDS families (table 1). Among the 51
families with BHDS: 25% (13/51) had FFs, a history of
spontaneous pneumothorax and renal tumours; 24% (12/51)
had both FFs and a history of spontaneous pneumothorax but
no renal tumours; 18% (9/51) had both FFs and kidney tumours
but no individuals with a history of pneumothorax; 24% (12/
51) had FFs but no renal tumour or history of pneumothorax;
4% (2/51) had no FFs, renal tumour or a history of
pneumothorax; 2% (1/51) had renal tumour but no FFs or a
history of pneumothorax; and 4% (2/51) had renal tumours and
a history of pneumothorax but no FFs (table 1).
Other clinical findings
Among the BHDS patients in the present study, two had
parotid gland oncocytomas diagnosed at ages 20 and 39 years.
Non-renal cancers that occurred among the BHDS patients
included two cases of colon cancer and thyroid cancer,
respectively; and single cases of squamous cell carcinoma
(SCC) of the head and neck, Hodgkin’s disease, uterine cancer,
prostate cancer, breast cancer, and SCC of the cervix. Other
tumours were rhabdomyoma and an adrenal mass (table 1).
Genotype–phenotype correlations
BHD mutation hotspot: c.1733insC and c.1733delC
There was no association between BHD mutation hot spot
versus all other BHD mutations, and presence of FFs (p=0.78),
presence of lung cysts (p=0.76) or presence of pneumothoraces
(p=1.0). We also investigated for genotype–phenotype correla-
tion among c.1733insC and c.1733delC BHD mutation carriers.
The frequency of individuals with histologically proven FFs was
similar among c.1733insC BHD mutation carriers (88% (22/25))
and c.1733delC BHD mutation carriers (78% (7/9)) (p=0.59).
Lung cysts were detected similarly among c.1733insC (84% (21/
25)) and c.1733delC BHD mutation carriers (100% (9/9))
(p=0.55). History of spontaneous pneumothorax was some-
what more common among c.1733delC (56% (5/9)) mutation
carriers than among c.1733insC carriers (32% (8/25)) but not
statistically significant (p=0.25). Renal tumours were more
common among c.1733delC (56% (5/9)) than c.1733insC (24%
(6/25)) BHD mutation carriers but not statistically significant
(p=0.11). To explore further potential genotype–phenotype
correlations we combined the BHD mutation hotspot data from
our present and previous study.
6 Our analyses showed that
c.1733insC mutation carriers and c.1733delC mutation carriers
had similar frequencies of FFs (85% (66/78) vs 84% (27/32)
p=1.00), lung cysts detected on thoracic CT scans (86% (56/65)
vs 84% (22/26) p=1.00), spontaneous pneumothorax (36% (31/
87) vs 40% (14/35) p=0.68) and renal tumours (29% (19/65) vs
24% (6/25) p=0.79). Therefore, in general there were no
statistically significant phenotypic differences among
c.1733insC and c.1733delC carriers in BHDS families seen at
NCI.
Other types of mutations
There was no association between BHD mutation status (no
mutation vs mutation), mutation types ((insertion, deletion,
nonsense, missense and splice site) (insertion vs other types of
mutation), (deletion vs other types of mutation), (nonsense vs
Original article
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mutation), (missense vs other types of mutation), (frameshift
vs other types of mutation), (intron vs exon mutations)), and
cutaneous affected ((FF vs no FF) or (FF vs TD and/or PFF)),
lung cyst (lung cyst vs no lung cysts ) or pneumothorax (history
of pneumothorax vs no history of pneumothorax) in our cohort
of patients.
Review of published reports of BHD germline mutations
We reviewed cases with published BHD germline mutations and
general clinical characteristics associated with BHDS.
5–15 We
previously reported 177 patients (88 men and 89 women) with
BHD mutations from 51 BHDS families.
6 Excluding the BHDS
patients reported by NCI,
6 a total of 85 individuals with BHD
germline mutations have been reported including 35 women, 41
men and nine individuals in whom the gender was unspecified
ranging from 12–77 years of age
5 7–15 (table 2). The number of
affected individuals in a family ranged from 1–12.
BHD germline mutations
Excluding our previously reported 22 BHD germline muta-
tions,
4618 unique BHD germline mutations have been reported
by other investigators including: seven deletion, three insertion,
three nonsense, and five splice-site mutations (table 2).
5 7–15 Of a
total of 40 BHD germline mutations reported to date, only four
mutations (c.1065-6delGCinsTA, c. 1733insC, c. 1733delC and
1884C.T) were reported by both the NCI BHDS group and
other investigators.
4–9 12–14 A family with the c.875delC mutation
was described in two different studies.
78BHD mutations have
been reported affecting all translated exons,
4–14 with the
exception of exons 8 and 10.
4–15 Exon 11 was the most frequent
site of mutations (c.1733insC/1733delC, c.1755G.C) present in
125 individuals from 40 unrelated BHDS families.
4–9 12–14 The hot
spot mutation (c.1733insC or c.1733delC) was the most
common BHD mutation reported to date in a total of 124
individuals from 39 BHDS families.
4–9 12–14 Seventy-nine indivi-
duals from 28 families (18 NCI and 10 other groups) were
reported to have the c.1733insC mutation and 45 individuals
from 11 families (nine NCI and two other groups) were reported
as having the c.1733delC mutation.
4–9 12–14
The most 59 BHD mutation reported occurred at nucleotide
454 (c. 458delG) in exon 4 affecting the initiator codon of
BHD.
14 Other BHD germline mutations have been previously
reported in exon 4: c.690delTCGG predicted to result in a
termination codon 50 amino acids downstream
11 and c.514delT
predicted to result in a premature termination codon at codon
34.
6 The most 39 mutation reported occurred at nucleotide 2034
(c.2034 C.T) in exon 14 and was predicted to produce a
premature termination codon at codon 527.
6 No additional BHD
mutations have been reported in exon 14.
Clinical features
In the previously reported NCI BHDS cohort, 143 patients with
BHD mutations had their skin papules biopsied and evaluated
histologically. Of these 143 cases, 122 (85%) were diagnosed with
a histologically proven FF.
6 Excluding the NCI BHDS patients
reported,
6 73% (43/59) of individuals with germline mutations
in BHD had a histologically confirmed FF (table 2).
5 7–15 In
five individuals with germline BHD mutations, FF was
not confirmed histologically but they had a histologically
proven trichodiscoma.
8
We previously reported 35 patients with BHD germline
mutations who developed renal tumours.
6 The frequency of
renal tumour among patients with BHD germline mutations
seen at the NIH clinical centre or in field trips was 22% (35/162)
or 20% (35/177) of all patients of whom blood was collected and
screened for mutations.
6 Two BHDS patients died of metastatic
kidney cancer after radical nephrectomy.
31 One patient under-
went bilateral nephrectomies for multiple tumours and received
a kidney transplant. Pathological examination revealed that his
Table 2 Summary of reviewed reports with BHD germline mutations and general clinical characteristics, excluding National Cancer Institute reports
Reference
No. of
patients
Clinical FF (Bx FF)
(pos/neg/unk)
Renal tumour med Hx,
and/or CT or MRI
(yes/no/unk)
Lung cysts
(pos/neg/unk)
Hx pneumo
(yes/no/unk) Germline mutations
Khoo et al 2002
5 21 Pos 16/21 (16 Bx+) Yes 2/15; Unk 6 Unk 21/21 Yes 8/21 c.1733delC, c.1733insC
Van Steensel et al 2007
7 6 Pos 6/6 (6 Bx+) No 5/5; 1 Unk Neg 5/5 Yes 1/5 c.1863-1873delGGGAGCCCTGT
Ukn 1 1 Unk c.1755G.C, c. 875delC,
c.1733insC, IVS10-2 A.G
Leter et al 2008
8 23 Pos 18/23 (18 Bx+) Yes 2/25 Ukn 25/25 Yes 4/25 c.1065-6delGCinsTA,
2 Ukn c.1733insC, c.875delC, c.1110dupG
c.1756-7del11;1778delCinsGA
c.IVS 6-1 G.A
Gunji et al 2007
9 5 Neg 5/5 No 5/5 Pos 5/5 Yes 5/5 c. IVS5-1delgtccctccag,
HRCT c.1795 insCCACCCT, c.1733insC
c.1988delGATG, c.857delC
Graham et al 2005
10 11 Ukn 11/11 No 11/11 Pos 6/6 Yes 10/10 c.1398G.T, c.1884C.T
Ukn 5 1 Ukn
Painter et al 2005
11 12 Unk 12/12 No 12/12 Pos 12/12 Yes 5/12 c.690-3delTCGG
Kawasaki et al 2005
12 2 Pos 2/2 (2 Bx+) No 2/2 Unk 2/2 No 2/2 c.1733insC
Lamberti et al 2005
13 1 Pos 1/1 (Bx+) Ukn Unk Ukn c.1733insC
Bessis et al 2006
14 2 Pos 1/2 (1 Bx+) No 2/2 1 Neg; 1 Unk Yes 1/2 c.458delG
Murakami et al 2007
15 1 Ukn 1 Yes Neg No c.1733insC
Chest CT
Total 85* 43/59 Pos(43 Bx+) Yes 5/77 23/30 Pos Yes 33/82
Ukn 26 Ukn 8 Ukn 55 Ukn 3
Bx, biopsy; CT, computed tomography; FF, fibrofolliculoma; HRCT, high resolution computed tomography; Hx, medical history; MRI, magnetic resonance imaging; Neg, negative;
Pos, positive; Ukn, unknown.
*One case was reported twice.
78
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and the other tumours had multiple histologies. This patient had
biopsy proven paraspinal metastasis (clear cell histology)
56 months after his initial surgery and he died shortly thereafter.
The otherpatienthad an8 cm predominantlyclear cell RCCwith
areas of tubular papillary and chromophobe histology that
invaded the perinephric fat. This patient had retroperitoneal
recurrence 5 months after surgery, eventually developed osseous
metastases and died 20 months postoperatively.
31
Excluding previous NCI BHDS reports,
6 overall in the
literature five of 77 (6.5%) individuals with BHD germline
mutations had a recorded medical history of kidney tumours
and/or renal tumour on renal imaging (table 2). The age at
diagnosis of a renal tumour ranged from 20–55 years.
581 5Khoo
and co-workers reported a 65-year-old BHDS patient with a
history of right nephrectomy at age 20 for clear cell RCC, and an
additional patient who at age 35 had a nephrectomy for an 8 cm
‘‘malignant oncocytoma’’ infiltrating the capsule.
5 The latter
patient developed metastatic disease involving the right upper
lobe of the lung which upon thoracotomy revealed metastatic
RCC with papillary structures. Microscopic re-examination of
tumour tissue revealed unclassified RCC, Fuhrman grade 4.
5
Leter and co-workers reported an individual with a history of
RCC who had unilateral mixed papillary and clear cell RCC at
age 39 and a year later died due to metastatic disease.
8 In
addition, Murakami et al reported a 55-year-old who at the time
of nephrectomy had a 9.5 cm single solid mass, an inferior vena
cava tumour thrombus and lung metastasis.
15 Microscopic
examination of renal tumour showed tubular and tubulo-
papillary areas with mainly eosinophilic neoplastic cells and
focally clear cells. This patient died of metastatic disease
27 months after nephrectomy. Of 50 individuals with a germ-
line BHD mutation who were screened for kidney tumours by
other investigators,
5 7–15 only one had a renal tumour detected
on baseline imaging (table 2).
8 This patient was a 40-year-old
woman with histologically confirmed trichodiscoma who was
referred by the dermatologist for renal imaging. Renal work-up
revealed RCC with elements of oncocytoma.
In our previous study, we found that 33% (57/171) of
patients with BHD germline mutations for whom medical
history was available reported a history of spontaneous
pneumothorax and 87% (95/109) of BHDS who were screened
by chest CT scan had one or more lung cysts.
6 Excluding the
BHDS patients reported by NCI,
6 77% (23/30) of patients
reported with BHD germline mutations had lung cysts on CT
imaging and 40% (33/82) of patients reported a history of
spontaneous pneumothorax (table 2).
5 7–15
DISCUSSION
We report the clinical findings in 50 new families with BHDS
and 13 novel BHD germline mutations. We identified BHD
mutations in 88% of BHDS families which is slightly higher
than our previously reported mutation detection rate of 84%.
6
In combination with our previous reports,
46to date we have
reported 102 families and 36 unique BHD germline mutations
including 21 insertion/deletions, eight putative splice site, six
nonsense and one missense mutation (fig 3). Including the
present study and all cases worldwide, 53 unique germline BHD
mutations have been reported affecting all translated exons (4-
14), with the exception of exons 8 and 10 (4-15). In this
Figure 3 BHD germline mutation reported by the National Cancer Institute (NCI) group and other investigators. (A) Illustration of the 55 germline BHD
mutations identified by the NCI. The 23 unique BHD mutations identified in the present study are shown in red. The star indicates mutations identified in
both the present study and the previous NCI study.
6 The 22 unique mutations previously reported by NCI are shown in black.
6 (B) Lower panel shows
the 18 germline BHD mutations reported by other investigators.
5 7–15 Mutations shown in blue were identified by both the NCI group and other
investigators. The parenthesis show the original nomenclature used in the original reports.
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(K508R) in BHD (fig 2). Using sequence alignment, we found
that the lysine508 amino acid in folliculin is conserved in
vertebrate and invertebrate species suggesting functional
significance. The K508R mutation was present in a patient
with bilateral multifocal renal oncocytomas, a phenotype
commonly seen in BHDS, suggesting that it is a disease-causing
mutation. This mutation was not present in DNA from 160
unrelated control individuals. Therefore, although uncommon,
germline BHD missense mutations may occur in BHDS. This is
not surprising since a missense mutation in exon 7 (H255R) in
the canine BHD ortholog is the disease-associated germline
mutation in hereditary multifocal renal cystadenocarcinoma
and nodular dermatofibrosis in German shepherd dogs.
21 The
H255R mutation confers an amino acid change in a highly
conserved histidine of folliculin.
Including the present study, 70 patients with BHD germline
mutation and kidney tumours have been reported in the
literature.
5681 5 In the present NCI study, the age at diagnosis
of kidney tumours was similar to our previous reports
63 1and
reports by other investigators.
57 – 1 5Even though in the present
study we did not identify BHDS patients with metastatic
kidney cancer, only five BHDS patients with BHD mutations
who died of metastatic kidney cancer have been reported to
date.
5 8 15 31 These individuals with metastatic kidney cancer had
tumours with clear cell, tubulo-papillary and/or papillary
histologic features. These histologic features are slightly
different from most kidney tumours associated with BHDS.
BHDS is associated with a unique histological spectrum of
bilateral and multifocal kidney tumours ranging from hybrid
oncocytic (67%) to chromophobe RCC (23%) to oncocytic
(3%).
31 Clear cell RCC (3%) has also been reported in a few
BHDS cases.
31 Prospective studies with a larger number of
patients are needed to determine whether the different renal
tumour histopathologic subtypes associated with BHDS have
different malignant potentials. It is of interest that even though
95% of patients with BHD germline mutations and kidney
tumours have been reported by the NCI, to our knowledge only
two cases from the NCI group have developed metastatic
kidney disease.
31 In contrast, only a few BHDS patients with a
BHD germline mutation have been reported by other investi-
gators to have kidney tumours, and most (three of five) of these
cases had metastatic disease.
5 7–15 These differences may be a
reflection of the different ascertainment and screening meth-
odologies for kidney tumour used by different research groups.
The present investigation confirms the high prevalence of
kidney tumours in our BHDS families. Previously, we observed a
sevenfold increased risk of renal tumours in patients with
BHDS.
32 In the present study, using a combined ascertainment
in dermatologic and urologic oncology clinics at NCI, the overall
prevalence of kidney tumours among individuals with germline
BHD mutations was 34%. This frequency is higher than our
previous report (23%)
6 and much higher than the frequency of
kidney tumours in BHDS cases combined from other investi-
gators (6.5%). We also observed that BHDS patients with a
family history of kidney tumours had a statistically significant
risk of developing kidney tumours compared with BHDS
patients without a family history of kidney tumours
(p=0.0015). The risk remained significant when we excluded
cases ascertained on the basis of kidney tumour. Kidney tumour
is also a major phenotypic feature with high penetrance in the
naturally occurring BHDS animal models.
17 18 However, other
genetic and environmental factors may also be involved in the
development of kidney tumours in patients of BHDS and
animal models.
Renal tumours associated with BHDS may have a higher
impact on morbidity than on mortality. The presence of
oncocytosis in the renal parenchyma at surgery or at post-
mortem examination of patients with BHDS is histologic
evidence of the potential of kidney tumour development in
BHDS patients. The diagnosis in a family member and
surveillance of families with BHDS should lead to identification
of patients at high risk of BHDS kidney tumours and to early
detection and treatment. The use of nephron sparing surgery
rather than radical nephrectomy decreases the morbidity of
BHDS patients with renal tumours by preserving renal
functional tissue. The diagnosis of BHDS is of critical
importance in a patient presenting with kidney tumours since
the management of these tumours is different from sporadic
kidney tumours.
31 Somatic BHD mutations or LOH at the BHD
locus have been detected in 70% of RCCs from BHDS patients.
24
The high frequency of second hits in BHD and bhd supports that
it is a tumour suppressor gene. Inactivation of both BHD alleles
occurs in several histologic subtypes of RCC, suggesting that
inactivation of BHD occurs at an early stage of renal
tumorigenesis.
24
In the present study, we found that 84% of patients with
BHD germline mutations have pulmonary cysts on chest CT.
This is very similar to our previous study (89%)
6 but slightly
higher than other reports combined (77%)
5 7–15 In the present
study we found that 38% (34/89) of individuals with a BHD
germline mutation had a history of spontaneous pneu-
mothorax. This is very similar to all other studies combined
and our previous study (33%).
6 In the present study, we also
observed that patients with BHDS and a family history of
pneumothorax had a statistically significant increased risk of
pneumothorax when compared to BHDS patients without a
family history of spontaneous pneumothorax. This supports
previous reports of families with BHD mutations and a
prominent and almost exclusive spontaneous pneumothorax
inherited in an autosomal dominant fashion.
10 11 Most cases
with lung phenotype without other cutaneous or renal
manifestations probably are undetected cases of BHDS since
they are from cross sectional studies and cases may develop
other manifestations with time. Therefore, prospective follow-
up clinical studies of this group of patients are needed to
understand better how they fit within the spectrum of clinical
manifestations of BHDS.
Previously, we reported a 50-fold increased risk for the
development of spontaneous pneumothorax in patients with
BHDS compared with family members unaffected by BHDS.
32
The role of lung cysts in the mechanism leading to a spontaneous
pneumothorax in BHDS had not been established. Lung cysts
appear to be a precursor lesion leading to a spontaneous
pneumothorax. Recently, we reported that total lung cyst
volume, largest cyst diameter and volume, as well as every
parameter associated with lung cysts which we evaluated, were
significantly associated with pneumothorax in patients with
BHDS.
33 Haploinsufficiency may be responsible for the develop-
ment of lung cysts, skin lesion and other hamartomas associated
with BHDS. We have not observed increased mortality or
progressive lung deterioration in BHDS patients with lung cysts
or pneumothorax. The lung phenotype (history of spontaneous
pneumothorax and lung cysts) associated with BHDS is a
prominent feature that helps to distinguish BHDS from other
inherited kidney cancer syndromes (von Hippel–Lindau
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hereditary papillary renal cell carcinoma).
34–37
We also report in this study for the first time families with
germline mutations in BHD and angiofibroma, perifollicular
fibroma or both angiofibroma and perifollicular fibromas as
their only BHDS cutaneous phenotype. Our findings support
that BHDS is associated with a spectrum of cutaneous
hamartomas ranging from AF to PFF to FF. BHDS associated
hamartomas should be distinguish it from other genoderma-
toses with an increased risk for internal malignancy.
38 Recently,
a BHD mutation was reported in one of three families with only
trichodiscomas.
8 However, two of the three families had an
atypical presentation and most likely do not have BHDS. In
addition, we previously reported additional individuals with
BHD germline mutations and trichodiscomas.
6 It is of interest
that we identified two individuals with germline mutations in
BHD who also had a history of malignant melanoma. Only one
previous confirmed case of melanoma in a BHDS patient has
been reported.
5 We also identified a BHDS family in whom one
sibling developed a DFSP and another sibling had a cutaneous
leiomyosarcoma. These tumours are rare and not previously
reported in BHDS. We also identified two additional individuals
with parotid gland tumours for a total of six cases in our group of
102 BHDS families
6 and a total of eight cases reported to date.
39
Most of the other internal neoplasms identified in this study
have been previously reported in patients with BHDS.
5 40–45
However, determining whether they are part of the clinical
spectrum of BHDS remains to be investigated in further studies.
In this study, we investigated potential genotype–phenotype
relationships in our patients with BHDS. In general, we found
no associations between specific BHD mutations or mutation
types (intron vs exon; frameshift, nonsense, missense) and
clinical phenotype (FF, TD/AF, PFF, renal tumours, sponta-
neous pneumothorax, or lung cysts). Previously, we reported
that individuals with an BHD IVS9+2 mutation had a higher
frequency of kidney tumours compared to all mutation carriers.
6
In this study, only one family had this same mutation, thus this
observation could not be confirmed. It is possible that aberrant
mutant BHD proteins produced by splice site mutations have
functional consequences and lead to renal tumorigenesis.
Each of our independent studies and combined analyses
showed that c.1733insC and c.1733delC mutation carriers had
similar frequencies of FFs, lung cysts and pneumothoraces. In a
previous study, we found that the frequency of renal tumours in
c.1733delC carriers was lower than the frequency of renal
tumours in c.1733insC carriers.
6 However, analysis of combined
data from both studies showed no significant differences in
frequencies of renal tumours among both groups. Future studies
with combined data from large cohorts of BHDS families should
have enough statistical power to confirm our studies and
evaluate other potential genotype–phenotype correlations.
The majority of BHD germline mutations identified in this
investigation, both of our studies combined and all studies
combined, are predicted to produce a C-terminally truncated
folliculin (FLCN) resulting in loss of function.
4–15 In this study, we
report a mutation in a family in which a BHD mutation was not
previously detected.
6 Re-sequencing DNA from family 240, who
linked to chromosome 17p11.2, revealed that affected haplotype
carriers had a putative splice site mutation in the BHD gene
within intron 4 (IVS4-2 A.G) (table 1). However, we did not
identify sequence variations in the coding region and 39 and 59
regulatoryregionsof BHD inseven additional familiesdespite two
attempts using direct DNA sequencing. Future studies will
include screening families for large deletions in BHD.
Recently, Baba and co-workers
26 reported that FLCN interacts
with FNIP1 through its C terminus. Therefore, germline
mutations predicted to produce a C-terminally truncated
FLCN would be unable to bind FNIP1. These investigators also
showed that FLCN phosphorylation facilitated by FNIP1 is
reduced by inhibitors of mTOR and AMPK activity implicating
FLCN/FNIP1 in the AMPK and mTOR signalling pathways.
26
Recently, Henske and co-workers deleted the BHD homolog in
Schizosaccharomyces pombe.
46 They showed that expression
profiling revealed that six permease and transporter genes,
known to be down-regulated in Deltatsc1 and Deltatsc2, were
up-regulated in Deltabhd. They also showed that loss of Bhd
sensitised yeast to rapamycin induced increases in permease
expression levels, and rapamycin induced lethality in Deltabhd
yeast expressing the hypomorphic Rhb1 allele.
46 These results
suggest that Bhd activates Tor2.
Advances in the diagnosis of BHDS using molecular genetic
techniques has allowed us to expand the BHDS phenotypic
spectrum of associated hamartomas and tumours, and demon-
strate clinical heterogeneity both within and among BHDS
families. Although we report a large group of families, our
dataset is too small to examine genotype–phenotype correla-
tions rigorously. However, this should be possible in the future
by combining our clinical and BDH mutation data on clinically
well described BHDS patients and families with that from other
centres. Future characterisation of BHD mutations and geno-
type–phenotype correlations in BHDS may provide valuable
insights into the molecular pathogenesis of BHDS. Future
clinical studies and laboratory investigations using in vitro
systems and animal models may help us to elucidate the
sequence of pathogenetic events that lead to the clinical findings
and the organ preference of involvement that we observe in
BHDS.
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